MN-08 is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MN-08’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MN-08 overview

MN-08 is under development for the treatment of pulmonary arterial hypertension (PAH), including idiopathic pulmonary arterial hypertension, acute ischemia, vascular dementia, glaucoma, Alzheimer's disease and unspecified indication. The drug candidate is a nitric ester derivative memantine. It targets N-methyl-D-aspartate (NMDA) glutamate receptors. It is administered through oral route.

Guangzhou Magpie Pharmaceutical overview

Guangzhou Magpie Pharmaceutical., is a drug developer. The company is headquartered in China.

For a complete picture of MN-08’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.